US 7713947 & US 8377903 - Cladribine Regimen for Treating Multiple Sclerosis, relate to dosage regimen (947 claim 36: oral administration of cladribine in a total dosage of about 1.7 to 3.5 mg/kg over a short induction period, followed by extended cladribine-free intervals and subsequent maintenance courses)
A vast number of preclinical and clinical studies have provided evidence for the potential role of GLP-1R agonists in modulating reward-seeking of food, alcohol, cocaine, and amphetamine, offering the possibility of a novel therapeutic alternative for treating addiction [112]
Eka Widiastuti IA, Arsyad A, Idris I, Patellongi I, Kadriyan H, Buanayuda GW, Sari DP, Rosyidi RM
Help Secure Permanent Affordable Access to GLP-1 Medications The Issue WHY SIGN THIS PETITION Every year, 500,000 people in the U.S